FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF	CHANGES IN	BENEFICIAL	OWNERSHIP
--------------	------------	-------------------	------------------

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Feener Edward P. (Last) (First) (Middle) C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E					3. Do 08/2	2. Issuer Name and Ticker or Trading Symbol KalVista Pharmaceuticals, Inc. [KALV] 3. Date of Earliest Transaction (Month/Day/Year) 08/17/2023 4. If Amendment, Date of Original Filed (Month/Day/Year)								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director				
(Street) CAMBRIDGE MA 02142						X Form filed by One Reporting Person Form filed by More than One Reporting Person											I	
(City)	(Sta		Zip)	Non Doriu		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											1 to	
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y			on	n 2A. Deemed Execution Date,		ate,	3. Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and		(A) or	5. Amount of Securities Beneficially Owned Follo		Form lly (D) o ollowing (I) (In		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		ansaction(s) str. 3 and 4)			(Instr. 4)
Common Stock 08/17/20)23	M 11,494 A (1) 7		78	3,265		D							
Common Stock 08/18/20)23				S ⁽²⁾		4,976	D	\$10.7287	7(3) 73,289			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, if any			Transaction of Code (Instr. Derivative		vative urities uired or losed o) cr. 3, 4	Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exer	: rcisable	Expiration Date	Title	Amount or Number of Shares					
Restricted Stock Unit	(1)	08/17/2023			M			1,773		(4)	(4)	Commo Stock	n 1,773	\$0.00	19,512	2	D	
Restricted Stock Unit	(1)	08/17/2023			M			2,430		(5)	(5)	Commo Stock	n 2,430	\$0.00	21,875	5	D	
Performance Stock Unit	(6)	08/17/2023			M			7,291		(7)	(7)	Commo Stock	ⁿ 7,291	\$0.00	0		D	

Explanation of Responses:

- 1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- 2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and performance stock units ("PSUs"). The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$10.7280 to \$10.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set
- 4. 1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.
- 5. 1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, for a period of three years, subject to continued service through each vesting date.
- 6. Each PSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- 7. Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on June 8, 2023. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Data and Enrollment Metrics goals ("Performance Metrics"). 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of August 17, 2023, upon Performance Metrics achieved, subject to continued service through each vesting date.

Remarks:

/s/ Benjamin L. Palleiko, Attorney-in-Fact ** Signature of Reporting Person

08/21/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.